Shares of Gilead Sciences GILD decreased 0.8% in after-market trading after the company reported Q2 results.
Earnings per share increased 68.47% year over year to $1.87, which beat the estimate of $1.73.
Revenue of $6,217,000,000 higher by 20.88% year over year, which beat the estimate of $6,070,000,000.
The upcoming fiscal year's EPS expected to be between $6.90 and $7.25.
The upcoming fiscal year's revenue expected to be between $24,400,000,000 and $25,000,000,000.
How To Listen To The Conference Call
Date: Jul 29, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/29gud5xf
Recent Stock Performance
52-week high: $75.04
52-week low: $56.56
Price action over last quarter: Up 9.50%
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.